Viewing Study NCT02087059


Ignite Creation Date: 2025-12-24 @ 2:53 PM
Ignite Modification Date: 2026-02-24 @ 3:14 PM
Study NCT ID: NCT02087059
Status: COMPLETED
Last Update Posted: 2016-07-11
First Post: 2014-03-12
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
Sponsor: Novartis Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Myelofibrosis (MF) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Post-Polycythemia Vera (PV) MF View
None Post-Essential Thrombocythemia (ET) MF View